All News
Filter News
Found 2,543 articles
-
Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference
1/2/2019
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 37th annual J.P. Morgan Healthcare Conference.
-
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
-
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
NACD New England Chapter Names Leaders in Corporate Governance as 2019 ‘Director of the Year’ Honorees
12/20/2018
Honored are Moderna, Vertex Pharmaceuticals, and Peter Brooke, Dorothy Puhy, and Greg Shell
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer
12/13/2018
Foghorn® Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on insights into genetic mutations in the chromatin regulatory system, and Flagship Pioneering, a unique life science innovation enterprise, today announced the appointment of Carl P. Decicco, Ph.D., as Foghorn’s new chief scientific officer (CSO
-
The long-awaited and massively hyped initial public offering of Moderna Therapeutics hit the market yesterday. The company sold approximately 26.3 million shares priced at $23 a share. This exceeded the revised goal of $600 million by about $4.3 million.
-
Moderna Announces Pricing of Initial Public Offering
12/7/2018
Moderna, Inc. today announced the pricing of its initial public offering of 26,275,993 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts and commissions.
-
Moderna Therapeutics raised some eyebrows last week when it refiled with the Securities and Exchange Commission (SEC), raising its goal for its initial public offering from $500 million to $600 million. The company, which has no products on the market, is fantastic at raising money, but some anal...
-
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
-
The Cambridge, Mass.-based biotech company, which had proposed a $500 million initial public offering (IPO) earlier this month, came back Wednesday with a new goal of $600 million.
-
Flagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader Award
11/15/2018
Flagship Pioneering today announced the recipient of the firm's annual Pioneering Leader Award.
-
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
-
As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).
-
In a survey of more than 8,000 people in the biotech and pharma industry for Science, Regeneron Pharmaceuticals, topped the list.
-
Alexion Reports Third Quarter 2018 Results
10/24/2018
3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase
-
Newly Published Data in Nature Medicine Show Potential of mRNA to Produce Therapeutic and Protective Protein Levels in Pre-Clinical Models of Acute Intermittent Porphyria
10/8/2018
Moderna, Inc., today announced new pre-clinical research published in the journal Nature Medicine that further demonstrates the utility of its mRNA platform to express therapeutic levels of protein in liver tissue to potentially treat patients with rare metabolic disorders.
-
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.